Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
|||
| Line 6: | Line 6: | ||
=History of changes in FDA indication= | =History of changes in FDA indication= | ||
| − | *6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] | + | *6/27/2018: Initial FDA approval in combination with [[Binimetinib (Mektovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. |
=Also known as= | =Also known as= | ||
Revision as of 17:06, 10 January 2020
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Binimetinib (Mektovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Also known as
- Code name: LGX818
- Brand name: Braftovi